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1. Introduction
  Gastric cancer, known as a malignant tumor[1], is 
characterized by tumor cell invasion and metastasis and 
is also a main cause of death[2]. Ki67 is widely used as 
a marker of cell proliferation and its function is closely 
associated with chromatin. β-catenin exhibits the roles of 
signal transduction and cellular adhesion in Wnt signaling 
pathway. Amplification of Her-2/neu gene is the key to the 
efficacy of molecular targeted drugs. We investigated the 
correlations of β-catenin, Ki67 and Her-2/neu with the 
clinical characteristics of gastric cancer and analyzed the 
relationship between the expression of β-catenin, Ki67 and 
Her-2/neu proteins. Reliable reference indices were also 
searched to screen Her-2/neu gene state.  
2. Materials and methods
2.1. General data
  Cancerous gastric tissue samples were surgically resected 
from 101 gastric cancer patients who received treatment 
at Shandong Provincial Hospital, China between March 
2012 and May 2013. Simultaneously, fresh stomach mucous 
membrane tissues, which was confirmed pathologically 
free of carcinomatous change, were harvested from the 
Objective: To study the clinical pathologic characteristics of β-catenin, Ki67 and Her-2/neu 
in gastric cancer and the correlation of β-catenin and Ki67 to the protein expression and gene 
conditions of Her-2/Neu. Methods: The protein expression of β-catenin, Ki67 and Her-2/Neu 
was detected by immunohistochemistry in 101 cases of gastric cancer and the gene conditions 
of Her-2/Neu by fluorescence in situ hybridization (FISH). Results: The protein expression of 
β-catenin, Ki67 and Her-2/Neu had close relationship with the clinical pathologic characteristics 
of gastric cancer. The β-catenin and Ki67 had obvious correlation to the differentiation, 
infiltration and lymphatic metastasis of the gastric cancer (P<0.05). The Ki67 had close 
relationship with the tumor-node-metastasis staging staging of gastric cancer (P<0.05). 
Her-2/Neu had close relationship with the differentiation and tumor-node-metastasis staging of 
gastric cancer (P<0.05) but had no relationship with the infiltration and lymphatic metastasis of 
the gastric cancer (P<0.05). The protein expression of Ki67 had significantly positive correlation 
to the protein expression and gene amplification conditions of Her-2/Neu (r=0.567, P<0.05 for 
protein; r=0.304, P<0.05 for gene). Conclusions: Combined detection of β-catenin, Ki67 and 
Her-2/Neu can be used as a reliable method to help the observation of biological behavior, 
diagnosis and prognosis of gastric cancer, and Ki67 can be used to serve the preliminary 
screening of Her-2/Neu gene state.
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cutting edge of diseased foci of 76 gastric cancer patients 
and used as control. The included patients did not receive 
any anti-tumor treatment before surgery and provided 
complete clinical record document. Following hematoxylin-
eosin staining, all tissue sections were diagnosed as 
adenocarcinoma by two experienced physicians in 
consensus. The gastric cancer patients, 52 males and 49 
females, were at the age of 57 (range from 34 to 80) years. 
The size of tumor was ≥5 cm in 70 patients and <5 cm in 
31 patients. According to the WHO criteria, tumor cells 
were well- and medium-differentiated in 51 patients and 
poorly-differentiated in 50 patients. As per the pathological 
tumor-node-metastasis staging (pTNM) system issued by the 
American Joint Commission for Cancer Staging (2011), tumors 
were staged as I/II in 58 patients and as III-IV in 43 patients. 
According to the depth of invasion, tumors invaded the 
serosa in 57 patients and had invaded but not penetrated the 
serosa in 44 patients. Lymph node metastasis was present in 
68 patients but not in 33 patients.  
2.2. Main instruments and reagents
  The experimental instruments used in this study were 
provided by Department of Pathology, Shandong Provincial 
Hospital, China. Other instruments included paraffin 
embedding apparatus (Germany), microtomes (LEICA 
BM2135; AO, USA), optical microscope (BX-50; Olympus, 
Japan), constant temperature baker (Shanghai Yuejin 
Medical Instrument Factory, China), and in situ hybridizer 
(ThermoBriteTM, StatSpin, USA). Immunohistochemical 
reagents were purchased from Beijing Zhongshan Golden 
Bridge Biotechnology Co., Ltd., China. Her-2/neu gene 
fluorescence in situ hybridization (FISH) detection kits and 
reagents were purchased from Beijing Jinpujia Medical 
Science and Technology Co., Ltd., China. 
2.3. Immunohistochemical staining assay
  Immunohistochemical staining was performed using 
streptavidin-peroxidase kit according to the manufacturer’s 
instructions. PBS, rather than primary antibody, was taken 
as a negative control. Through an optical microscopy, 
β-catenin- and Ki67-positive cells were counted in five 
fields of view randomly selected from each section. The 
percentage of β-catenin- or Ki67-positive cells ≤10% was 
considered as 0 point, 11%-50% as 1 point, 51%-75% as 2 
points, and >75% as 3 points. No staining was scored 0, light 
brown 1 point, brown 2 points, and dark brown 3 points. The 
final score was obtained by sum of the above two scores: 
1-2 points were considered as “1+”, 3-4 points as “2+” and 
“5-6” points as “3+”. Finally, sample with a total score 
of 0 was considered as negative, while sample with a total 
score of 1+ to 3+ as positive. Her-2/neu immunoreactivity 
was scored according to HercepTest guidelines. Her-2/neu-
positive cells exhibited brown yellow staining.
2.4. FISH detection
  FISH detection was performed in strict accordance with kit 
instruction. Thirty cells were counted for calculation of ratio 
value according to the formula: 
Ratio = Number of red signals in 30 nuclei/Number of green 
signals in 30 nuclei. 
  Ratio <1.8 was considered negative, indicating absence 
of Her-2/neu gene amplification in the tested sample; 
Ratio >2.2 was considered positive, indicating presence 
of Her-2/neu gene amplification in the tested sample; 
1.8≤Ratio≤2.2, count 100 cells or repeat FISH test. 
2.5. Statistical analysis
  Statistical analysis was performed using SPSS 17.0 software. 
Difference comparison was carried out using Chi-square test 
and Fisher’s exact test. Correlation analysis was conducted 
using Spearman’s rank correlation. A level of P<0.05 was 
considered statistically significant.
3. Results 
3.1. Expression of β-catenin, Ki67 and Her-2/neu proteins 
in cancerous gastric tissue
  As shown by the immunohistochemical staining, the 
positive expression of β-catenin and Ki67 was located in the 
nuclei (Figure 1A and 1B), and that of Her/neu was found in 
the cellular membrane (Figure 1C). The positive cells were 
stained light or dark brown. The expression of Her-2/neu 
gene was also detected by FISH. The red signals of Her-2/neu 
gene amplification (positive) were distributed in clusters or 
diffusion spots (ratio >2.2; Figure 2A), while the signals were 
distributed in diffusion spots (ratio <1.8; Figure 2B) without 
Her-2/neu gene amplification. 
A                              B                              C                              D
Figure 1. Expression of 毬-catenin, ki67 and Her-2/neu in the tested 
samples detected by immunohistochemistry (×200). 
(A) 毬-catenin-positive expression (3+); (B) Ki67-positive expression 
(3+); (C) Her-2/neu-positive expression (3+); (D) Her-2/neu-negative 
expression.
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A                                                                B
Figure 2. Amplification of Her-2/neu gene in the tested sample 
detected by in situ hybridization (×200). 
(A) With Her-2/neu gene amplification (ratio >2.2); (B) Without 
Her-2/neu gene amplification (ratio <1.8). Her-2/neu gene is shown 
by red signals and centromere 17 by green signals
  Among the 101 patients with gastric cancer, the number 
of β-catenin-positive patients scored 0, 1+, 2+ and 3+ 
was 26(25.7%), 4(4%), 29(28.7%) and 42(41.6%), respectively, 
while the number of Ki67-positive patients was 20(19.8%), 
24(23.8%), 15(14.8%) and 42(41.6%), respectively. The number 
of Her-2/neu-positive patients scored 2+ and 3+ was 6(6.0%) 
and 10(10.0%), respectively. The percentage of β-catenin-, 
Ki67-, and Her-2/neu-positive patients among the 101 
gastric cancer patients was 74.3%(75/101), 80.2%(81/101) and 
15.8%(16/101), respectively, which was significantly higher 
than that of the control group [36.8%(28/76), 25.0%(19/76) and 
1.3%(1/76), P<0.05].
3.2. Correlations of β-catenin, Ki67 and Her-2/neu 
expression with the clinical pathological characteristics of 
gastric cancer 
  The expression of β-catenin, Ki67 and Her-2/neu was not 
correlated with the gender, age, and tumor size of patients 
with gastric cancer. The expression of β-catenin and Ki67 
were significantly correlated with degree of tumor cell 
differentiation, depth of tumor cell invasion and lymph 
node metastasis (P<0.05). The β-catenin expression was 
not correlated with pTNM stage. The Her-2/neu expression 
was significantly correlated with pTNM stage (P<0.05), but it 
was not correlated with the depth of tumor cell invasion and 
lymph node metastasis (Table 1). 
3.3. Correlations of Ki67 protein expression with Her-2/neu 
protein expression and gene stage 
  The Ki67 protein expression was positively correlated 
with Her-2/neu protein expression (r=0.567, P<0.05) and 
positively correlated with Her-2/neu gene state (r=0.304, 
P<0.05). The immunohistochemistry results showed 
that the positive rate of Her-2/neu expression (21.4%) 
was significantly higher in the 9 gastric cancer patients 
presenting with the positive expression of Ki67 (3+) and 
Her-2/neu (3+) than in other types (Table 2). 
Table 1
Correlations of 毬-catenin, Ki67 and Her-2/neu with the clinical pathological characteristics of gastric cancer.
Characteristic 毬
-catenin Ki67 Her-2/neu
Positive rate (%) 氈
2 P Positive rate (%) 氈
2 P Positive rate (%) 氈
2 P
Sex Male 71.15(37/52)
0.540 0.502
84.62(44/52)
0.920 0.445
17.31(9/52)
0.173 0.444
Female 77.55(38/49) 75.51(37/49) 14.29(7/49)
Age (years) ≥60 72.50(29/40)
0.107 0.744
77.50 (31/40)
0.304 0.616
12.50(5/40)
0.555 0.581
<60 75.41(46/61) 81.97(50/61)   18.03(11/61)
Tumor diameter (cm) ≥5 72.86(51/70)
0.234 0.806
81.43(57/70)
0.217 0.787
  17.14(12/70)
0.290 0.770
<5 77.42(24/31) 77.42(24/31) 12.90(4/31)
Degree of tumor cell differentiation Well/medium 60.78(31/51)
9.783 0.003
70.59(36/51)
5.991 0.023
  7.84(4/51)
4.944 0.031
Poor 88.00(44/50) 90.00(45/50)   24.00(12/50)
Depth of tumor cell invasion Not invade serosa 64.91(37/57)
5.978 0.021
71.93(41/57)
5.632 0.018
14.04(8/57)
0.320 0.594
Invade serosa 86.36(38/44) 90.91(40/44) 18.18(8/44)
Lymph node metastasis Yes 80.88(55/68)
4.778 0.330
86.76(59/68)
5.561 0.031
  14.71(10/68)
0.201 0.772
No 60.61(20/33) 66.67 (22/33) 18.18(6/33)
Tumor-node-metastasis staging I+II stages 79.31(46/58)
1.820 0.250
72.41(42/58)
5.198 0.023
  8.62(5/58)
5.328 0.028
III+IV stages 67.44(29/43) 90.70(39/43)   25.58(11/43)
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3.4. Analysis on Her-2/neu protein expression and Her-2/neu 
gene state 
  Through FISH, the amplification of Her-2/neu gene 
was detected in 14 patients, with a gene amplification 
rate of 13.9%(14/101). According to the Her-2/neu protein 
expression, the patients were divided into two groups: 
Her-2/neu (2+/3+) and Her-2/neu (-/+). The amplification 
rates of Her-2/neu gene in the sanples with Her-2/neu 
(3+) and Her-2/neu (2+) were 90.0%(9/10) and 83.3%(5/6), 
respectively. In the tested samples with Her-2/neu (-/1+), 
no amplification of the Her-2/neu gene was detected (0/33 
and 0/52, respectively). The detection results of patients 
with Her-2/neu (2+/3+) by immunohistochemistry was 87.5% 
consistent with the amplification resluts of Her-2/neu gene 
by FISH. 
4. Discussion
  Abnormal or up-regulated expression of β-catenin leads 
to the occurrence of diseases[3]. It has been evidenced that 
β-catenin influences the biological behaviors of tumor stem 
cells[4] and its down-regulation improves cell ultrastructure, 
promotes apoptosis and inhibits cell proliferation[5]. We 
found β-catenin was significantly correlated with degree 
of tumor cell differentiation, depth of tumor cell invasion 
and lymph node metastasis (P<0.05), suggesting that 
abnormal β-catenin expression in the gastric cancer tissue 
helps gastric cancer cells to obtain stronger invasive and 
metastatic abilities and thus indicates poor prognosis. 
  At present, Ki67 has been considered as a reliable index 
for evaluating cell proliferation and malignant potentials and 
predicting cancer recurrence[6-7], and its expression level 
is of important clinical significance for tumor treatment and 
metastasis[8]. It also shows a predictive value in adjuvant 
chemotherapy. In our study, the Ki67 expression rate was 
70.6% in the well- and medium-differentiated gastric 
cancer, 90% in the poorly differentiated gastric cancer, 
68.6% in the serous layer-infiltrated tissues and 90.9% in 
the non-infiltrated tissues. The results suggest that changes 
in proliferative activity of tumor cells are related to the 
progression of gastric cancer.
  Her-2/neu, also called C-erbB-2, shows similar functions 
as Ki67 and both can promote mitosis. In this study, the 
positive expression rate of Her-2/neu was 15.8%, which 
is in accordance with a previous report[9]. The positive 
expression rate of Her-2/neu was 3.4% and 8.8% in the well- 
and medium-differentiated tissue and poorly differentiated 
tissue respectively, suggesting that high expression level of 
Her-2/neu is a marker of malignant tumor. Moreover, the 
amplification rate of Her-2/neu gene increased with the 
increasing grades, indicating the state of Her-2/neu gene 
becomes more instable with increasing malignance of gastric 
cancer.
  The application of Her-ceptin, the monoclonal antibody 
against Her-2/neu, in the treatment of gastric cancer 
attracts more attention and disputes. Trastuzumab (trade 
name: herceptin), a molecular targeted drug, is only 
effective in tumor patients presenting with Her-2/neu 
gene amplification. Her-2/neu (2+) was previously used as 
the reference for FISH detection of Her-2/Neu gene, but 
negative FISH detection results also exist in subjects with 
Her-2/neu (3+). To predict the Her-2/neu gene state of 
tumor patients more simply and accurately, we statistically 
analyzed the present results and found that the expression 
of Ki67 protein was positively correlated with the protein 
expression and gene amplification of Her-2/neu (r=0.567, 
P<0.05 for protein; r=0.304, P<0.05 for gene). The Her-2/neu 
gene amplification analyzed by FISH was consistent with 
the protein expression detected by immunohistochemistry, 
with a K value of 0.879, demonstrating that the protein 
expression and gene state had good consistency. This is in 
line with previous reports. However, contrary results have 
also been reported, which may be caused by differences in 
experimental methods, interpretation criteria and sample 
size. Further investigation is needed to eliminate this 
conflict. 
  Our results demonstrated that the protein expression and 
gene amplification of Her-2/neu were closely related to 
the expression of Ki67 protein. Previous researches show 
that Her-2/neu protein does not act independently but 
exhibits synergic and inhibitory effects together with other 
factors. Further studies are required to investigate whether 
the proliferative activity of gastric cancer cells promotes 
the Her-2/neu gene amplification and whether there is a 
Table 2
Correlations of Ki67 protein expression with Her-2/neu protein expression and gene stage. 
Ki67 protein expression
Her-2/neu protein expression
r P
Amplification of Her-2/neu gene
r P
++ +++ Yes No
++ 2 1 0.567 0.043 3 12 0.304 0.022 
+++ 1 9 2 40 
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regulatory relationship between Ki67 and Her-2/neu. We 
can speculated that the Ki67 protein expression, in addition 
to Her-2/neu (2+) protein expression, may be selected as 
another assistant reference in screening Her-2/neu gene 
state by FISH. 
  Taken together, the expression of β-catenin, Ki67 and 
Her-2/neu is closely related to the clinical pathological 
characteristics of gastric cancer. Combined detection 
methods can provide an overall reference evidence for 
understanding the nature, clinical diagnosis and prognosis 
of tumors. Her-2/neu combined with Ki67 can be used as 
a predicator for screening Her-2/neu gene state by FISH, 
which will increase detection efficiency of Her-2/neu gene 
amplification.
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